![]() DBTX lost -2. Over the past year the S&P 500 has fallen -8.74 while DBTX has risen 6.57. So far 17,148 shares have traded compared to average volume of 92,324 shares. The stock has traded between 2.74 and 2.90 so far today. DBTX has risen 0.95 from the previous closing price of 3.59 on volume of 307,630 shares. Decibel Therapeutics Inc (DBTX) stock is trading at 2.90 as of 1:27 PM on Thursday, Mar 23, a gain of 0.20, or 7.41 from the previous closing price of 2.70. Investor Contact: Julie Seidel Stern IR, Inc. Decibel Therapeutics Inc (DBTX) stock is up 26.4 while the S&P 500 is down -0.91 as of 2:42 PM on Wednesday, Feb 8. (NASDAQ:DBTX) insider upped their holding by 63 earlier this year. Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy SummitīOSTON, (GLOBE NEWSWIRE) - Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing andĭecibel Therapeutics (DBTX) Receives a Hold From SVB Securitiesĭecibel Therapeutics Initiates CHORD Phase 1/2 Clinical Trial of DB-OTO Hearing Loss Gene Therapy >DBTXĭecibel Therapeutics 1Q Cash Position $87.9M >DBTXĭecibel Therapeutics Q1 2023 Net Loss Of $(13.30)M Compared To $(14.02)M YoY Cash Balance Of $87.9M Will Fund Its Planned Operating Expenses Into 1H Of 2024ĭecibel Therapeutics (NASDAQ:DBTX) will report on Q1 2023. For more information about Decibel Therapeutics, please visit or follow us on Twitter. Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
0 Comments
Leave a Reply. |